Desogestrel plus testosterone effectively suppresses spermatogenesis but also causes modest weight gain and high-density lipoprotein suppression

Fertility and Sterility

Volumn 74, Issue 4, 2000, Pages 707-714

  Anawalt, Bradley D ^a   Herbst, Karen L ^a   Matsumoto, Alvin M ^b   Mulders, Titia M T ^a   Coelingh Bennink, Herjan J T ^c   Bremner, William J ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NV ORGANON   (Netherlands)

^c VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

Azoospermia; Desogestrel; Gonad otropins; Male hormonal contraception; Oligoazoospermia; Spermatogenesis; Testosterone

Indexed keywords

DESOGESTREL; HIGH DENSITY LIPOPROTEIN; LEVONORGESTREL; MALE CONTRACEPTIVE AGENT; TESTOSTERONE;

ACNE; ADULT; ARTICLE; AZOOSPERMIA; BODY WEIGHT DISORDER; CLINICAL TRIAL; CONTRACEPTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; GYNECOMASTIA; HORMONE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; LIPOPROTEIN BLOOD LEVEL; MALE; NORMAL HUMAN; OLIGOSPERMIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SPERMATOGENESIS; SPERMATOZOON COUNT; WEIGHT GAIN;

ACNE VULGARIS; ADULT; BLOOD CHEMICAL ANALYSIS; CHOLESTEROL; CONTRACEPTIVE AGENTS, MALE; CONTRACEPTIVES, ORAL, HORMONAL; CONTRACEPTIVES, ORAL, SYNTHETIC; DESOGESTREL; GYNECOMASTIA; HUMANS; LEVONORGESTREL; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; OLIGOSPERMIA; SPERM COUNT; SPERMATOGENESIS; TESTOSTERONE; WEIGHT GAIN;

EID: 0033795352     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(00)01490-4     Document Type: Article

References (19)

1. Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet. 336:1990;955-959.
2. Contraceptive efficacy of testosterone-induced azoospermia and oligo-azoospermia in normal men. Fertil Steril. 65:1996;821-829.
3. Amory JK, Bremner WJ. The use of testosterone as a male contraceptive. In: S Bhasin, editor. The therapeutic role of androgens. Baillieres Clinics in Endocrinology 1998;7(12):1977-85.
4. Wu F.C.W. Male contraception. Baillieres Clin Obstet Gynaecol. 10:1996;1-23.
5. Bagatell C.J., Herman J.R., Matsumoto A.M., Rivier J.E., Bremner W.J. Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men. J Clin Endocrinol Metab. 79:1994;561-567.
6. Meriggiola M.C., Bremner W.J. Progestogen-androgen combination regimens for male contraception. J Androl. 18:1997;240-243.
7. Bebb R.A., Anawalt B.D., Christensen R.B., Paulsen C.A., Bremner W.J., Matsumoto A.M. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone a promising male contraceptive approach . J Clin Endocrinol Metab. 81:1996;757-762.
8. Anawalt B.D., Bebb R.A., Bremner W.J., Matsumoto A.M. A lower-dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher-dosage combinations. J Androl. 20:1999;407-414.
9. Darney P.D. The androgenicity of progestins. Am J Med. 98:1995;104-110.
10. Matsumoto A.M., Paulsen C.A., Hopper B.R., Rebar R.W., Bremner W.J. Human chorionic gonadotropin and testicular function stimulation of testosterone, testosterone products, and sperm production despite high estradiol levels . J Clin Endocrinol Metab. 56:1983;720-728.
11. 2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem. 28:1982;1379-1388.
12. Warnick G.R. Enzymatic methods for the quantification of lipoprotein lipids. Albers J.J., Segrest J.P. Methods in enzymology. 129:1982;101-123 Academic Press, Orlando.
13. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without the use of the preparative centrifuge. Clin Chem. 18:1972;499-501.
14. Bremner W.J., Matsumoto A.M., Sussman A.M., Paulsen C.A. Follicle-stimulating hormone and human spermatogenesis. J Clin Invest. 68:1981;1044-1052.
15. Gordon D.L., Moore D.L., Thorslund T., Paulsen C.A. The determination of size and concentration of human sperm with an electronic particle counter. J Lab Clin Med. 65:1965;506-512.
16. Laboratory manual for the examination of human semen and sperm-cervical mucus interaction. 3rd ed. 1993;7-8 Cambridge University Press, Cambridge.
17. Wu F.C.W., Balasubramanian R., Mulders T.M.T., Coelingh-Bennink H.J.T. Oral progestin combined with testosterone as a potential male contraceptive additive effects between desogestrel and testosterone in suppression of spermatogenesis, the pituitary-testicular axis, and lipid metabolism . J Clin Endocrinol Metab. 84:1999;112-122.
18. Triglyceride, high-density lipoprotein, and coronary heart disease. J Am Med Assoc. 269:1993;505-511.
19. Meriggiola M.C., Bremner W.J., Paulsen C.A., Valdiserri A., Incorvaia L., Motra R., et al. A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive. J Clin Endocrinol Metab. 81:1996;3018-3023.